<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946673</url>
  </required_header>
  <id_info>
    <org_study_id>LUN0036</org_study_id>
    <nct_id>NCT00946673</nct_id>
  </id_info>
  <brief_title>Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat
      given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer
      (NSCLCA) brain metastases in patient with 1-4 lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose of vorinostat with concurrent radiosurgery will be determined.</measure>
    <time_frame>30 days following Stereotactic Radiosurgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>During the expanded phase I portion of the study, the safety of the Maximum tolerated dose dose will be confirmed.</measure>
    <time_frame>30 days following Stereotactic Radiosurgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The radiologic response, defined as local control and distant intra-cranial control rates at 3-months following radiotherapy, will be determined.</measure>
    <time_frame>3 months following Stereotactic Radiosurgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The short-term (&lt; 30 days post-treatment) and long-term (&gt; 30 days post-treatment) adverse effects will be determined.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The 12-month survival rate from the date of Stereotactic Radiosurgery will be determined.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Lung Cancer</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>vorinostat &amp; stereotactic radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Orally up to 400 mg</description>
    <arm_group_label>vorinostat &amp; stereotactic radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Single fraction stereotactic radiotherapy - Standard of Care</description>
    <arm_group_label>vorinostat &amp; stereotactic radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients age 18 years and older with histologically proven non-small cell lung
             cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior
             surgery or radiation is allowed as long as the target metastatic lesion(s) has not
             been treated with previous radiation.

          -  Adequate organ function (section 3.1.10).

          -  ECOG performance status 0-2.

          -  Life expectancy of &gt;=12 weeks.

          -  Systemic chemotherapy washout period &gt;=7 days.

        Exclusion Criteria:

        Patients who have previously been treated with whole brain irradiation, pediatric patients
        (age &lt;18), pregnant women, and patients who are unable to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Griffith R. Harsh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Griffith R Harsh</investigator_full_name>
    <investigator_title>Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

